Most lung nodules are not cancer. In one large study, only 6% of lung nodules progressed to lung cancer over three years, and in another screening study the rate was as low as 0.7%. The vast majority turn out to be harmless clusters of immune cells, old scars, or other benign tissue. Still, some nodules do represent early-stage lung cancer, and certain features make that more or less likely.
What Most Lung Nodules Actually Are
The most common type of benign lung nodule is an infectious granuloma, a small cluster of immune cells that forms in response to a past fungal infection or tuberculosis. Many people develop these without ever knowing they were sick. Autoimmune conditions like rheumatoid arthritis and sarcoidosis can also produce granulomas in the lungs.
Other benign causes include hamartomas (small growths of normal tissue in an unusual arrangement), scarring from smoking or chemical exposure, and tiny intrapulmonary lymph nodes. These nodules sit quietly in the lungs and rarely cause symptoms, which is why they’re almost always discovered by accident during a CT scan ordered for something else entirely.
Size Is the Strongest Clue
Nodule size is one of the most reliable indicators of cancer risk. Solid nodules smaller than 6 mm carry such low risk that current guidelines from the Fleischner Society recommend no routine follow-up for low-risk patients. Between 6 and 8 mm, the risk increases enough to warrant a follow-up CT scan in 6 to 12 months. Above 8 mm, doctors typically move faster, considering a PET scan or tissue biopsy within about three months.
For solid nodules larger than 5 mm, one study found a malignancy rate of 4.5%. That still means roughly 19 out of 20 were benign, but it’s enough to justify closer monitoring. Solid nodules overall have a cancer risk of only about 1%.
Nodule Type Matters More Than You’d Expect
Not all lung nodules look the same on a scan, and the type of nodule changes the picture significantly. There are three categories: solid, ground-glass, and part-solid.
- Solid nodules appear as dense as blood vessels on a CT scan. They’re the most common type and the least likely to be cancer, with an overall malignancy rate around 7%.
- Ground-glass nodules look hazy and faint, like frosted glass. These carry a malignancy rate of about 18%.
- Part-solid nodules contain both hazy and dense areas. They have the highest cancer risk at roughly 63%.
This is counterintuitive for many people. A faint, wispy-looking nodule is actually more concerning than a bright, solid one. Part-solid nodules, though less common (about 21% of nodules found during screening), are strongly associated with slow-growing cancers and get the most careful monitoring. If a part-solid nodule persists and its solid portion grows to 6 mm or larger, it’s considered highly suspicious.
What the Shape and Edges Tell Your Doctor
Radiologists look closely at the borders and internal features of a nodule. Smooth, well-defined edges are more common in benign nodules. A polygonal shape, meaning the nodule has multiple flat sides like a gem, is also a reassuring sign, as are certain calcification patterns. Nodules with dense, central, or “popcorn” style calcification are almost always benign, typically granulomas or hamartomas.
On the other hand, spiky or spiculated edges radiating outward (sometimes called a “corona radiata” sign) are strongly associated with malignancy. Lobulated or scalloped borders fall somewhere in between. Visible air passages running through a nodule are more often seen in cancerous growths, particularly adenocarcinoma. None of these features alone confirms or rules out cancer, but together they help doctors estimate risk.
How Growth Rate Separates Cancer From Benign Nodules
Cancer cells divide, so malignant nodules grow. Benign nodules typically stay the same size. A nodule that hasn’t changed over two years of follow-up scans is generally considered benign.
Malignant solid nodules tend to double in volume every 30 to 400 days. Part-solid and ground-glass cancers grow more slowly, with average doubling times of roughly 600 and 850 days respectively. This is why ground-glass nodules may require follow-up scans for up to five years before doctors are confident they’re stable. A nodule that suddenly increases in size between scans gets immediate attention.
Personal Risk Factors That Shift the Odds
The same nodule carries different implications depending on who has it. Age is the strongest personal risk factor. People aged 56 to 65 are about 1.5 times more likely to have a clinically significant nodule than younger adults, and those over 66 face more than double the odds.
Smoking history matters substantially. Current smokers are about 1.5 times more likely to have a concerning nodule, and heavier smoking increases risk further. Former smokers carry a modestly elevated risk as well. Interestingly, family history of lung cancer appears to matter most for people who have never smoked, where it roughly doubles the odds of a clinically relevant nodule.
Doctors weigh all of these factors together. A 4 mm solid nodule in a 35-year-old nonsmoker is handled very differently from an 8 mm spiculated nodule in a 68-year-old with a 30-year smoking history.
How Doctors Decide What Happens Next
For most small nodules, the answer is simply watching and waiting. A follow-up CT scan after several months checks whether the nodule has grown. This is the most common path, and for the majority of people, the nodule stays the same size and eventually gets cleared.
For nodules larger than 8 mm or those with worrying features, a PET scan may be the next step. PET scans detect areas of unusually high metabolic activity, which cancer cells produce. In studies of nodules larger than 7 mm, PET scans correctly identified 96% of cancers and correctly cleared 76% of benign nodules. They’re good but not perfect: some infections and inflammatory conditions can light up on a PET scan, and very slow-growing cancers can sometimes be missed.
If imaging remains uncertain, a biopsy provides a definitive answer. The decision to biopsy depends on the estimated probability of cancer, the risks of the procedure itself (which vary depending on where the nodule sits in the lung), and your own preferences. For nodules in the intermediate-risk range, where imaging can’t clearly say benign or malignant, doctors will walk through these trade-offs with you.
What Follow-Up Schedules Look Like
Follow-up timelines depend on nodule size, type, and your risk profile. For solid nodules under 6 mm in low-risk patients, no follow-up is needed. Between 6 and 8 mm, expect a CT scan at 6 to 12 months and possibly another around 18 to 24 months. Nodules over 8 mm typically get evaluated within three months.
Ground-glass nodules over 6 mm are checked at 6 to 12 months to see if they persist, then monitored with scans every two years for up to five years. Part-solid nodules over 6 mm get a faster initial check at 3 to 6 months, and if the solid portion stays under 6 mm, annual scans continue for five years. If the solid component grows beyond 6 mm, the nodule is treated as highly suspicious.
These timelines can feel long, and the waiting is often the hardest part. But the schedules are designed around how quickly different types of nodules change. Slow-growing ground-glass nodules need years of observation precisely because they evolve so gradually. A nodule that stays stable through the full monitoring period carries very low residual risk.